A citation-based method for searching scientific literature

Johannes Oldenburg, Johnny N Mahlangu, Benjamin Kim, Christophe Schmitt, Michael U Callaghan, Guy Young, Elena Santagostino, Rebecca Kruse-Jarres, Claude Negrier, Craig Kessler, Nancy Valente, Elina Asikanius, Gallia G Levy, Jerzy Windyga, Midori Shima. N Engl J Med 2017
Times Cited: 488







List of co-cited articles
554 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Johnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, Claude Negrier, Markus Niggli, M Elisa Mancuso, Christophe Schmitt, Victor Jiménez-Yuste, Christine Kempton, Christophe Dhalluin,[...]. N Engl J Med 2018
297
67

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Steven W Pipe, Midori Shima, Michaela Lehle, Amy Shapiro, Sammy Chebon, Katsuyuki Fukutake, Nigel S Key, Agnès Portron, Christophe Schmitt, Maria Podolak-Dawidziak,[...]. Lancet Haematol 2019
140
43

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Guy Young, Ri Liesner, Tiffany Chang, Robert Sidonio, Johannes Oldenburg, Victor Jiménez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Marianne Uguen,[...]. Blood 2019
127
43

WFH Guidelines for the Management of Hemophilia, 3rd edition.
Alok Srivastava, Elena Santagostino, Alison Dougall, Steve Kitchen, Megan Sutherland, Steven W Pipe, Manuel Carcao, Johnny Mahlangu, Margaret V Ragni, Jerzy Windyga,[...]. Haemophilia 2020
326
29

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
Takehisa Kitazawa, Tomoyuki Igawa, Zenjiro Sampei, Atsushi Muto, Tetsuo Kojima, Tetsuhiro Soeda, Kazutaka Yoshihashi, Yukiko Okuyama-Nishida, Hiroyuki Saito, Hiroyuki Tsunoda,[...]. Nat Med 2012
270
28

Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Naoki Fukazawa, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami. N Engl J Med 2016
246
27

Guidelines for the management of hemophilia.
A Srivastava, A K Brewer, E P Mauser-Bunschoten, N S Key, S Kitchen, A Llinas, C A Ludlam, J N Mahlangu, K Mulder, M C Poon,[...]. Haemophilia 2013
20

A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
Midori Shima, Keiji Nogami, Sayaka Nagami, Seitaro Yoshida, Koichiro Yoneyama, Akira Ishiguro, Takashi Suzuki, Masashi Taki. Haemophilia 2019
58
32

A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.
Naoki Uchida, Takehiko Sambe, Koichiro Yoneyama, Naoki Fukazawa, Takehiko Kawanishi, Shinichi Kobayashi, Midori Shima. Blood 2016
151
18

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Marilyn J Manco-Johnson, Thomas C Abshire, Amy D Shapiro, Brenda Riske, Michele R Hacker, Ray Kilcoyne, J David Ingram, Michael L Manco-Johnson, Sharon Funk, Linda Jacobson,[...]. N Engl J Med 2007
17

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.
Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda, Yukiko Okuyama-Nishida, Chifumi Moriyama, Tetsuya Wakabayashi, Eriko Tanaka, Atsushi Muto, Tetsuo Kojima, Takehisa Kitazawa,[...]. PLoS One 2013
171
15


Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Ryu Kasai, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami. Blood Adv 2017
75
18


Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
Glaivy Batsuli, Karen L Zimowski, Kelly Tickle, Shannon L Meeks, Robert F Sidonio. Haemophilia 2019
41
29

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.
Yesim Dargaud, Anne Lienhart, Maissaa Janbain, Sandra Le Quellec, Nathalie Enjolras, Claude Negrier. Haematologica 2018
56
21



Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Michael U Callaghan, Claude Negrier, Ido Paz-Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse-Jarres, Maria Elisa Mancuso,[...]. Blood 2021
33
36

AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
Savita Rangarajan, Liron Walsh, Will Lester, David Perry, Bella Madan, Michael Laffan, Hua Yu, Christian Vettermann, Glenn F Pierce, Wing Y Wong,[...]. N Engl J Med 2017
364
11

Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
Jens Müller, Isabell Pekrul, Bernd Pötzsch, Beate Berning, Johannes Oldenburg, Michael Spannagl. Thromb Haemost 2019
34
32

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.
Takehisa Kitazawa, Keiko Esaki, Tatsuhiko Tachibana, Shinya Ishii, Tetsuhiro Soeda, Atsushi Muto, Yoshiki Kawabe, Tomoyuki Igawa, Hiroyuki Tsunoda, Keiji Nogami,[...]. Thromb Haemost 2017
95
11

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.
Amy D Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita,[...]. Blood 2019
51
19


The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.
Manuel Carcao, Carmen Escuriola-Ettingshausen, Elena Santagostino, Johannes Oldenburg, Ri Liesner, Beatrice Nolan, Angelika Bátorová, Saturnino Haya, Guy Young. Haemophilia 2019
49
20

Definitions in hemophilia: communication from the SSC of the ISTH.
V S Blanchette, N S Key, L R Ljung, M J Manco-Johnson, H M van den Berg, A Srivastava. J Thromb Haemost 2014
345
10

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
Johnny Mahlangu, Jerry S Powell, Margaret V Ragni, Pratima Chowdary, Neil C Josephson, Ingrid Pabinger, Hideji Hanabusa, Naresh Gupta, Roshni Kulkarni, Patrick Fogarty,[...]. Blood 2014
315
10

Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
Assaf A Barg, Einat Avishai, Ivan Budnik, Sarina Levy-Mendelovich, Tami B Barazani, Gili Kenet, Tami Livnat. Pediatr Blood Cancer 2019
39
25

The hemophilias--from royal genes to gene therapy.
P M Mannucci, E G Tuddenham. N Engl J Med 2001
684
9

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.
K John Pasi, Savita Rangarajan, Pencho Georgiev, Tim Mant, Michael D Creagh, Toshko Lissitchkov, David Bevan, Steve Austin, Charles R Hay, Inga Hegemann,[...]. N Engl J Med 2017
197
9

Impact of inhibitors on hemophilia A mortality in the United States.
Christopher E Walsh, J Michael Soucie, Connie H Miller. Am J Hematol 2015
88
10

Emicizumab treatment and monitoring in a paediatric cohort: real-world data.
Assaf A Barg, Tami Livnat, Ivan Budnik, Einat Avishai, Tami Brutman-Barazani, Ilia Tamarin, Dalia Bashari, Mudi Misgav, Gili Kenet. Br J Haematol 2020
29
31

Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.
A Muto, K Yoshihashi, M Takeda, T Kitazawa, T Soeda, T Igawa, Y Sakamoto, K Haraya, Y Kawabe, M Shima,[...]. J Thromb Haemost 2014
70
11

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers.
Naoki Kotani, Koichiro Yoneyama, Nobuhiko Kawakami, Tohru Shimuta, Hiroyuki Fukase, Takehiko Kawanishi. Clin Pharmacol Drug Dev 2019
19
42

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
Amit C Nathwani, Edward G D Tuddenham, Savita Rangarajan, Cecilia Rosales, Jenny McIntosh, David C Linch, Pratima Chowdary, Anne Riddell, Arnulfo Jaquilmac Pie, Chris Harrington,[...]. N Engl J Med 2011
8


Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
Giancarlo Castaman, Cristina Santoro, Antonio Coppola, Maria E Mancuso, Rita C Santoro, Sergio Bernardini, Francesco R Pugliese, Riccardo Lubrano, Maria Golato, Armando Tripodi,[...]. Blood Transfus 2020
20
40

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
Amit C Nathwani, Ulreke M Reiss, Edward G D Tuddenham, Cecilia Rosales, Pratima Chowdary, Jenny McIntosh, Marco Della Peruta, Elsa Lheriteau, Nishal Patel, Deepak Raj,[...]. N Engl J Med 2014
762
8

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
K John Pasi, Savita Rangarajan, Nina Mitchell, Will Lester, Emily Symington, Bella Madan, Michael Laffan, Chris B Russell, Mingjin Li, Glenn F Pierce,[...]. N Engl J Med 2020
162
8

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A.
H Marijke van den Berg, Kathelijn Fischer, Manuel Carcao, Hervé Chambost, Gili Kenet, Karin Kurnik, Chris Königs, Christoph Male, Elena Santagostino, Rolf Ljung. Blood 2019
32
25

The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
Johannes Oldenburg, Johnny N Mahlangu, Willem Bujan, Peter Trask, Michael U Callaghan, Guy Young, Elina Asikanius, Flora Peyvandi, Elena Santagostino, Rebecca Kruse-Jarres,[...]. Haemophilia 2019
37
21

Hemophilia therapy: the future has begun.
Pier Mannuccio Mannucci. Haematologica 2020
63
12

Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.
Isabella McCary, Christine Guelcher, Jan Kuhn, Regina Butler, Gita Massey, Michael F Guerrera, Lance Ballester, Leslie Raffini. Haemophilia 2020
27
29


Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
P Vincent Jenkins, Annette Bowyer, Clive Burgess, Elaine Gray, Steve Kitchen, Paul Murphy, Sean Platton, Anne Riddell, Pratima Chowdary, Will Lester. Haemophilia 2020
27
25

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
Lindsey A George, Spencer K Sullivan, Adam Giermasz, John E J Rasko, Benjamin J Samelson-Jones, Jonathan Ducore, Adam Cuker, Lisa M Sullivan, Suvankar Majumdar, Jerome Teitel,[...]. N Engl J Med 2017
372
7

Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
Koji Yada, Keiji Nogami, Kenichi Ogiwara, Yasuaki Shida, Shoko Furukawa, Hiroaki Yaoi, Masahiro Takeyama, Ryu Kasai, Midori Shima. Int J Hematol 2019
27
25

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
Flora Peyvandi, Pier M Mannucci, Isabella Garagiola, Amal El-Beshlawy, Mohsen Elalfy, Vijay Ramanan, Peyman Eshghi, Suresh Hanagavadi, Ramabadran Varadarajan, Mehran Karimi,[...]. N Engl J Med 2016
283
7

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.
Samantha C Gouw, H Marijke van den Berg, Kathelijn Fischer, Günter Auerswald, Manuel Carcao, Elizabeth Chalmers, Hervé Chambost, Karin Kurnik, Ri Liesner, Pia Petrini,[...]. Blood 2013
208
7



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.